Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 6Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Esophageal Squamous Cell Carcinoma 4Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Nasopharyngeal Neoplasms 2Uterine Cervical Dysplasia 1Solid Tumors 1Solid Tumor 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HCC 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Childhood Brain Stem Neoplasm 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Pancreatic Cancer 1Advanced Colorectal Cancer 1Advanced Cancer 1

Interventions

nimotuzumab 1Sorafenib 1Radiofrequency Ablation 1Immune Checkpoint Inhibitors 1Hematologic Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HCC × nimotuzumab × Clear all
NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled

HCC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡